ASSESSMENT OF HEPATIC STEATOSIS BY ULTRASOUND-GUIDED ATTENUATION PARAMETER AND ATORVASTATIN TREATMENT OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Main Article Content
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease is common in patients with type 2 diabetes mellitus. Objectives: To assess hepatic steatosis using the ultrasoundguided attenuation parameter, related factors, and changes after three months of treatment. Materials and methods: This study at Van Hanh General Hospital from April 2025 to March 2026 included 93 patients in the baseline analysis and 70 patients in a single-arm before-and-after intervention using atorvastatin 20 mg/day plus lifestyle counseling. Results: Disease prevalence was 91.4%. After three months, the ultrasound-guided attenuation parameter decreased from 0.733 to 0.692 dB/cm/MHz and low-density lipoprotein cholesterol from 4.00 to 2.61 mmol/L; 54.3% improved by at least one steatosis grade. Conclusion: The ultrasound-guided attenuation parameter is useful for assessment and short-term monitoring.
Keywords
Metabolic dysfunction-associated steatotic liver disease, ultrasound-guided attenuation parameter, atorvastatin, type 2 diabetes mellitus, hepatic steatosis
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Cho EEL, Ang CZ, Quek J, Fu CE, Lim LKE, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: An updated systematic review and meta-analysis. Gut. 2023. 72(11), 2138-2148, doi: 10.1136/gutjnl-2023-330110.
3. Hoàng Thị Mỹ Hạnh, Nguyễn Quang Bảy. Đặc điểm lâm sàng, cận lâm sàng và một số yếu tố liên quan ở bệnh nhân đái tháo đường típ 2 có gan nhiễm mỡ không do rượu (NAFLD). Tạp chí Y học Việt Nam. 2024. 543(2), 204-208, doi : 10.51298/vmj.v543i2.11435.
4. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023. 79(6), 15421556, doi: 10.1016/j.jhep.2023.06.003.
5. European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024. 81(3), 492-542, doi: 10.1016/j.jhep.2024.04.031.
6. Eslam M, Fan JG, Yu ML, Wong VWS, Cua IH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease. Hepatol Int. 2025. 19(2), 261-301, doi: 10.1007/s12072-024-10774-3.
7. Imajo K, Toyoda H, Yasuda S, Suzuki Y, Sugimoto K, et al. Utility of ultrasound-guided attenuation parameter for grading steatosis with reference to MRI-PDFF in a large cohort. Clin Gastroenterol Hepatol. 2022. 20(11), 2533-2541.e7, doi: 10.1016/j.cgh.2021.11.003.
8. Bende F, Sporea I, Sirli R, Baldea V, Lazar A, et al. Ultrasound-guided attenuation parameter (UGAP) for the quantification of liver steatosis using the controlled attenuation parameter (CAP) as the reference method. Med Ultrason. 2021. 23(1), 7-14, doi: 10.11152/mu-2688.
9. American Diabetes Association Professional Practice Committee. 2. Diagnosis and classification of diabetes: Standards of Care in Diabetes-2025. Diabetes Care. 2025. 48(Suppl. 1), S27-S49, doi: 10.2337/dc25-S002.
10. Eslami Z, Aghili SS, Ghaleh Ghafi A. Atorvastatin on treatment of nonalcoholic fatty liver disease patients. Chonnam Med J. 2024. 60(1), 13-20, doi: 10.4068/cmj.2024.60.1.13.